Torrent Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 6/6

Torrent Pharmaceuticals verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 14.2%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 17%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 6.6%. Die Eigenkapitalrendite von Torrent Pharmaceuticals beträgt 24.2% und die Nettomargen betragen 15.4%.

Wichtige Informationen

13.6%

Wachstumsrate der Gewinne

13.6%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie17.5%
Wachstumsrate der Einnahmen7.2%
Eigenkapitalrendite25.3%
Netto-Marge15.8%
Letzte Ertragsaktualisierung30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Apr 16
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 03
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Feb 05
Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Jan 07
Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Nov 14
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jun 01
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Mar 01
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 25
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Jun 02
Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

May 25
Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Feb 18
A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Jan 27
Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Jan 04
Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

Dec 14
Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Nov 07
A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Sep 30
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Sep 01
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 02
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Jun 01
I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate

May 14
Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 23
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More

Mar 02
The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More

Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?

Feb 10
Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?

Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?

Jan 19
Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?

Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?

Dec 29
Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?

Aufschlüsselung der Einnahmen und Ausgaben

Wie Torrent Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NSEI:TORNTPHARM Einnahmen, Ausgaben und Erträge (INR Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 24109,95817,35420,6760
31 Mar 24107,27816,56420,1660
31 Dec 23104,74214,94219,6620
30 Sep 23102,33213,43218,9320
30 Jun 2398,64212,69217,8420
31 Mar 2396,20212,45217,0520
31 Dec 2292,5808,31216,2330
30 Sep 2288,7507,97215,8830
30 Jun 2287,2108,01215,8330
31 Mar 2285,0807,77215,4830
31 Dec 2183,15812,18915,2270
30 Sep 2182,02812,66914,9770
30 Jun 2180,82812,60914,7170
31 Mar 2180,04612,51914,5970
31 Dec 2080,14312,41714,3500
30 Sep 2079,85311,95714,2600
30 Jun 2079,73311,29714,2100
31 Mar 2079,39310,24714,4210
31 Dec 1978,4885,59314,3980
30 Sep 1979,3385,54314,5380
30 Jun 1978,2284,89314,3880
31 Mar 1976,7284,36314,0380
31 Dec 1875,1418,16113,7430
30 Sep 1869,8916,28112,7830
30 Jun 1865,1216,53112,1830
31 Mar 1859,4986,78111,3530
31 Dec 1756,7276,55610,6740
30 Sep 1756,3878,26610,2840
30 Jun 1756,3878,29610,0440
31 Mar 1758,1579,3369,9340
31 Dec 1659,15410,01410,2330
30 Sep 1660,14410,6249,9130
30 Jun 1662,74413,6449,3930
31 Mar 1666,66917,3328,4240
31 Dec 1563,31516,29918,6530
30 Sep 1559,60513,13918,5830
30 Jun 1554,8659,43918,7230
31 Mar 1546,5357,5098,7720
31 Dec 1447,2478,64916,5100
30 Sep 1445,7178,55916,3100
30 Jun 1443,2677,70915,8900
31 Mar 1441,8476,63915,7700
31 Dec 1338,2915,30813,9010
30 Sep 1336,1114,85813,6310

Qualität der Erträge: TORNTPHARM hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: TORNTPHARMDie aktuellen Gewinnspannen (15.4%) sind höher als im letzten Jahr (12.9%).


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: TORNTPHARMIn den letzten 5 Jahren sind die Gewinne von 14.2% jährlich gestiegen.

Beschleunigtes Wachstum: TORNTPHARMDas Gewinnwachstum des Unternehmens im letzten Jahr (33%) übertrifft seinen 5-Jahres-Durchschnitt (14.2% pro Jahr).

Erträge im Vergleich zur Industrie: TORNTPHARM Das Gewinnwachstum im vergangenen Jahr (33%) übertraf das der Branche Pharmaceuticals 18.4% .


Eigenkapitalrendite

Hohe Eigenkapitalrendite: TORNTPHARMDie Eigenkapitalrendite des Unternehmens (24.2%) wird als hoch angesehen.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren